(NASDAQ: LYRA) Lyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.88%.
Lyra Therapeutics's earnings in 2025 is -$38,836,000.On average, 2 Wall Street analysts forecast LYRA's earnings for 2025 to be -$30,356,621, with the lowest LYRA earnings forecast at -$42,196,690, and the highest LYRA earnings forecast at -$18,516,552. On average, 2 Wall Street analysts forecast LYRA's earnings for 2026 to be -$10,919,175, with the lowest LYRA earnings forecast at -$11,544,067, and the highest LYRA earnings forecast at -$10,294,282.
In 2027, LYRA is forecast to generate -$10,442,283 in earnings, with the lowest earnings forecast at -$10,442,283 and the highest earnings forecast at -$10,442,283.